{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:02:06Z","timestamp":1771038126397,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,3]]},"DOI":"10.1093\/jac\/45.3.329","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:24:55Z","timestamp":1027722295000},"page":"329-335","source":"Crossref","is-referenced-by-count":76,"title":["High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures"],"prefix":"10.1093","volume":"45","author":[{"given":"Federico","family":"Pea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Baraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Furlanut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,3]]},"reference":[{"key":"key\n\t\t\t\t20170411032718_R1","doi-asserted-by":"crossref","unstructured":"Wilhelm, M. P. (1991). Vancomycin. Mayo Clinic Proceedings66, 1165\u201370.","DOI":"10.1016\/S0025-6196(12)65799-1"},{"key":"key\n\t\t\t\t20170411032718_R2","doi-asserted-by":"crossref","unstructured":"Brown, D. L. & Mauro, L. S. (1988). Vancomycin dosing chart for use in patients with renal impairment. American Journal of Kidney Diseases11, 15\u201319.","DOI":"10.1016\/S0272-6386(88)80168-9"},{"key":"key\n\t\t\t\t20170411032718_R3","doi-asserted-by":"crossref","unstructured":"Lake, K. D. & Peterson, C. D. (1985). A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy5, 340\u20134.","DOI":"10.1002\/j.1875-9114.1985.tb03441.x"},{"key":"key\n\t\t\t\t20170411032718_R4","doi-asserted-by":"crossref","unstructured":"Matzke, G. R., McGory, R. W., Halstenson, C. E. & Keane, W. F. (1984). Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy25, 433\u20137.","DOI":"10.1128\/AAC.25.4.433"},{"key":"key\n\t\t\t\t20170411032718_R5","doi-asserted-by":"crossref","unstructured":"Moellering, R. C., Jr, Krogstad, D. J. & Greenblatt, D. J. (1981). Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Annals of Internal Medicine94, 343\u20136.","DOI":"10.7326\/0003-4819-94-3-343"},{"key":"key\n\t\t\t\t20170411032718_R6","doi-asserted-by":"crossref","unstructured":"Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokufa, H. Z., Rotschafer, J. C., Crossley, K. B. et al. (1988). Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy32, 848\u201352.","DOI":"10.1128\/AAC.32.6.848"},{"key":"key\n\t\t\t\t20170411032718_R7","doi-asserted-by":"crossref","unstructured":"Healy, D. P., Polk, R. E., Garson, M. L., Rock, D. T. & Comstock, T. J. (1987). Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrobial Agents and Chemotherapy31, 393\u20137.","DOI":"10.1128\/AAC.31.3.393"},{"key":"key\n\t\t\t\t20170411032718_R8","doi-asserted-by":"crossref","unstructured":"Moellering, R. C., Jr (1984). Pharmacokinetics of vancomycin. Journal of Antimicrobial Chemotherapy14, Suppl. D, 43\u201352.","DOI":"10.1093\/jac\/14.suppl_D.43"},{"key":"key\n\t\t\t\t20170411032718_R9","doi-asserted-by":"crossref","unstructured":"Chow, A. W. & Azar, R. M. (1994). Glycopeptides and nephrotoxicity. Intensive Care Medicine20, Suppl. 4, S23\u20139.","DOI":"10.1007\/BF01713979"},{"key":"key\n\t\t\t\t20170411032718_R10","doi-asserted-by":"crossref","unstructured":"Welty, T. E. & Copa, A. K. (1994). Impact of vancomycin therapeutic drug monitoring on patient care. Annals of Pharmacotherapy28, 1335\u20139.","DOI":"10.1177\/106002809402801201"},{"key":"key\n\t\t\t\t20170411032718_R11","doi-asserted-by":"crossref","unstructured":"Marra, F., Cairns, B. & Jewesson, P. (1996). Vancomycin serum concentration monitoring. The middle ground is best. Clinical Drug Investigation12, 105\u201318.","DOI":"10.2165\/00044011-199612020-00006"},{"key":"key\n\t\t\t\t20170411032718_R12","doi-asserted-by":"crossref","unstructured":"Leader, W. G., Chandler, M. H. H. & Castiglia, M. (1995). Pharmacokinetic optimisation of vancomycin therapy. Clinical Pharmacokinetics28, 327\u201342.","DOI":"10.2165\/00003088-199528040-00005"},{"key":"key\n\t\t\t\t20170411032718_R13","doi-asserted-by":"crossref","unstructured":"Pauly, D. J., Musa, D. M., Lestico, M. R., Lindstorm, M. J. & Hetsko, C. M. (1990). Risk of nephrotoxicity with combination vancomycin\u2013aminoglycoside antibiotic therapy. Pharmacotherapy10, 378\u201382.","DOI":"10.1002\/j.1875-9114.1990.tb03566.x"},{"key":"key\n\t\t\t\t20170411032718_R14","doi-asserted-by":"crossref","unstructured":"Rybak, M. J., Albrecht, L. M., Boike, S. C. & Chandrasekar, P. H. (1990). Nephrotoxicity of vancomycin, alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy25, 679\u201387.","DOI":"10.1093\/jac\/25.4.679"},{"key":"key\n\t\t\t\t20170411032718_R15","doi-asserted-by":"crossref","unstructured":"Fernandez de Gatta, M. D., Calvo, M. V., Hernandez, J. M., Caballero, D., San Miguel, J. F. & Dominguez-Gil, A. (1996). Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clinical Pharmacology and Therapeutics60, 332\u201340.","DOI":"10.1016\/S0009-9236(96)90060-0"},{"key":"key\n\t\t\t\t20170411032718_R16","doi-asserted-by":"crossref","unstructured":"Burton, M. E., Gentle, D. L. & Vasko, M. R. (1989). Evaluation of Bayesian method for predicting vancomycin dosing. Drug Intelligence and Clinical Pharmacy23, 294\u2013300.","DOI":"10.1177\/106002808902300404"},{"key":"key\n\t\t\t\t20170411032718_R17","doi-asserted-by":"crossref","unstructured":"Rodvold, K. A., Pryka, R. D., Garrison, M. & Rotschafer, J. C. (1989). Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Therapeutic Drug Monitoring11, 269\u201375.","DOI":"10.1097\/00007691-198905000-00009"},{"key":"key\n\t\t\t\t20170411032718_R18","doi-asserted-by":"crossref","unstructured":"Hurst, A. K., Yoshinaga, M. A., Mitani, G. H., Foo, K. A., Jeliffe, R. W. & Harrison, E. C. (1990). Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrobial Agents and Chemotherapy34, 1165\u201371.","DOI":"10.1128\/AAC.34.6.1165"},{"key":"key\n\t\t\t\t20170411032718_R19","doi-asserted-by":"crossref","unstructured":"Fernadez de Gatta, M. M., Fruns, I. & Dominguez-Gil, A. (1994). Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy14, 196\u2013201.","DOI":"10.1002\/j.1875-9114.1994.tb02808.x"},{"key":"key\n\t\t\t\t20170411032718_R20","unstructured":"Furlanut, M., Pea, F., Baraldo, M., Nardi, G., Di Silvestre, A., Bertolissi, M. et al. (1997). The importance of a bayesian pharmacokinetic approach in improving vancomycin therapeutic use. European Journal of Clinical Pharmacology52, Suppl., Second Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Berlin, Germany, 17\u201320 September 1997. Abstract 500, p. A158."},{"key":"key\n\t\t\t\t20170411032718_R21","doi-asserted-by":"crossref","unstructured":"Cockroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron16, 31\u201341.","DOI":"10.1159\/000180580"},{"key":"key\n\t\t\t\t20170411032718_R22","doi-asserted-by":"crossref","unstructured":"Anne, L., Hu, M., Chan, K., Colin, L. & Gottwald, K. (1989). Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Therapeutic Drug Monitoring11, 585\u201391.","DOI":"10.1097\/00007691-198909000-00017"},{"key":"key\n\t\t\t\t20170411032718_R23","unstructured":"Poirier, T. I. & Gindici, R. A. (1992). Survey of clinical pharmacokinetic software for microcomputers. Hospital Pharmacy27, 971\u20137."},{"key":"key\n\t\t\t\t20170411032718_R24","doi-asserted-by":"crossref","unstructured":"Craig, W. (1993). Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. European Journal of Microbiology and Infectious Diseases12, Suppl. 1, S6\u20138.","DOI":"10.1007\/BF02389870"},{"key":"key\n\t\t\t\t20170411032718_R25","doi-asserted-by":"crossref","unstructured":"Ackerman, B. H., Vannier, A. M. & Eudy, E. B. (1992). Analysis of vancomycin time\u2013kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrobial Agents and Chemotherapy36, 1766\u20139.","DOI":"10.1128\/AAC.36.8.1766"},{"key":"key\n\t\t\t\t20170411032718_R26","doi-asserted-by":"crossref","unstructured":"Larsson, A. J., Walker, K. J., Raddatz, J. K. & Rotschafer, J. C. (1996). The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic condition. Journal of Antimicrobial Chemotherapy38, 589\u201397.","DOI":"10.1093\/jac\/38.4.589"},{"key":"key\n\t\t\t\t20170411032718_R27","doi-asserted-by":"crossref","unstructured":"Rotschafer, J. C., Zabinski, R. A. & Walker, K. J. (1992). Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy12, Suppl., S64\u201370.","DOI":"10.1002\/j.1875-9114.1992.tb04499.x"},{"key":"key\n\t\t\t\t20170411032718_R28","doi-asserted-by":"crossref","unstructured":"MacGowan, A. P. (1998). Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Therapeutic Drug Monitoring20, 473\u20137.","DOI":"10.1097\/00007691-199810000-00005"},{"key":"key\n\t\t\t\t20170411032718_R29","doi-asserted-by":"crossref","unstructured":"Rybak, M. J., Albrecht, L. M., Berman, J. R., Warbasse, L. H. & Svensson, C. K. (1990). Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrobial Agents and Chemotherapy34, 792\u20135.","DOI":"10.1128\/AAC.34.5.792"},{"key":"key\n\t\t\t\t20170411032718_R30","doi-asserted-by":"crossref","unstructured":"Bauer, L. A., Black, D. J. & Lill, J. S. (1998). Vancomycin dosing in morbidly obese patients. European Journal of Clinical Pharmacology54, 621\u20135.","DOI":"10.1007\/s002280050524"},{"key":"key\n\t\t\t\t20170411032718_R31","doi-asserted-by":"crossref","unstructured":"Golper, T. A., Noonan, H. M., Elzinga, L., Gilbert, D., Brummett, R., Anderson, J. L. et al. (1988). Vancomycin pharmacokinetics, renal handling, and non renal clearances in normal human subjects. Clinical Pharmacology and Therapeutics43, 565\u201370.","DOI":"10.1038\/clpt.1988.74"},{"key":"key\n\t\t\t\t20170411032718_R32","unstructured":"Olsen, N. V. (1998). Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans. Danish Medical Bulletin45, 282\u201397."},{"key":"key\n\t\t\t\t20170411032718_R33","doi-asserted-by":"crossref","unstructured":"Mousdale, S., Clyburn, P. A., Mackie, A. M., Groves, N. D. & Rosen, M. (1988). Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: a study in normal health volunteers. British Journal of Clinical Pharmacology25, 555\u201360.","DOI":"10.1111\/j.1365-2125.1988.tb03345.x"},{"key":"key\n\t\t\t\t20170411032718_R34","doi-asserted-by":"crossref","unstructured":"Leier, C. V., Webel, J. & Bush, C. A. (1977). The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation56, 468\u201372.","DOI":"10.1161\/01.CIR.56.3.468"},{"key":"key\n\t\t\t\t20170411032718_R35","doi-asserted-by":"crossref","unstructured":"Lass, N. A., Glock, D. & Goldberg, L. I. (1988). Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation78, 1310\u201315.","DOI":"10.1161\/01.CIR.78.5.1310"},{"key":"key\n\t\t\t\t20170411032718_R36","unstructured":"Ludens, J. H., Hook, J. B., Brody, M. J. & Williamson, H. E. (1968). Enhancement of renal blood flow by furosemide. Journal of Pharmacology and Experimental Therapeutics163, 456\u201360."},{"key":"key\n\t\t\t\t20170411032718_R37","doi-asserted-by":"crossref","unstructured":"Williamson, H. E., Bourland, W. A., Marchand, G. R., Farley, D. B. & Van Orden, D. E. (1975). Furosemide induced release of prostaglandin E to increase renal blood flow. Proceedings of the Society for Experimental Biology and Medicine150, 104\u20136.","DOI":"10.3181\/00379727-150-38982"},{"key":"key\n\t\t\t\t20170411032718_R38","unstructured":"Nuutinen, L. S. & Tuononen, S. (1976). The effect of furosemide on renal blood flow and renal tissue oxygen tension in dogs. Annales Chirurgiae et Gynaecologiae65, 272\u20136."},{"key":"key\n\t\t\t\t20170411032718_R39","doi-asserted-by":"crossref","unstructured":"Ljubicic, N., Bilic, A. & Plavsic, V. (1992). Effect of propranolol on urinary prostaglandin E2 excretion and renal interlobar arterial blood flow after furosemide administration in patients with hepatic cirrhosis. European Journal of Clinical Pharmacology43, 555\u20138.","DOI":"10.1007\/BF02285102"},{"key":"key\n\t\t\t\t20170411032718_R40","unstructured":"Nivoche, Y., Contrepois, A., Cremieux, A. C. & Carbon, C. (1982). Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion, and interactions with furosemide. Journal of Pharmacology and Experimental Therapeutics222, 237\u201340."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/45\/3\/329\/13057418\/JAC453329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T23:44:04Z","timestamp":1704411844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/45.3.329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2000,3]]},"published-print":{"date-parts":[[2000,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/45.3.329","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}